We had patients and parents of patients come in to testify, and we heard a lot of testimony on the frustration of getting access to drugs and reimbursements, together with worries about provincial governments changing the rules halfway through. Is there anything we can do, from a federal pan-Canadian strategy perspective, to make this easier, to ensure that people or families who have to deal with rare diseases can have easier access or opportunities to get these drugs?
On November 6th, 2018. See this statement in context.